News:   •  Restaurants   •  Library Catalog   •  Library Activities  •  History   •  Facebook / X/Twitter / RSS

Monrovia's Xencor Gets Permission to Resume Study of Cancer Treatment

Monrovia's Xencor, Inc., a clinical-stage biopharmaceutical company developing antibodies for the treatment of cancer, autoimmune, asthma and allergic diseases, announced the Food and Drug Administration has lifted the partial clinical hold that was placed on the Phase 1 study of XmAb14045, an antibody for leukemia patients. The company is using an amended protocol which seeks to enhance the safety of patients in the study.

- Brad Haugaard

No comments:

Post a Comment